Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893757 | 0.80 | MAPT (0.50) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL1893755 | 0.80 | MAPT (0.50) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL1772846 | 0.78 | SMN1; SMN2 (0.40) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL1772384 | 0.76 | CYP3A4 (0.47) | MEN1CYP3A4KMT2A | |
| SCHEMBL1886531 | 0.71 | CYP3A4 (0.45) | KDM4EMEN1CYP3A4KMT2ANPC1 | |
| SCHEMBL1886532 | 0.71 | CYP3A4 (0.45) | KDM4EMEN1CYP3A4KMT2ANPC1 | |
| SCHEMBL1772517 | 0.70 | KDM4E (0.46) | KDM4ESMN1; SMN2ALDH1A1HTTMEN1 | |
| SCHEMBL17708945 | 0.68 | LMNA (0.40) | KDM4ESMN1; SMN2HTTMEN1CYP3A4 | |
| SCHEMBL1772130 | 0.67 | CYP3A4 (0.42) | KDM4EALDH1A1HTTMEN1CYP3A4 | |
| SCHEMBL7951769 | 0.66 | EDNRB (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326634-B1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20140235672-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2014-08-21 | — | — | US | disclosed |
| US-8759390-B2 | Chromene modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2326634-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20110112146-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-12 | — | — | US | disclosed |
| WO-2010009069-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235672-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR3, CCR2 | KDM4E 4127/4885SMN1; SMN2 3612/4885ALDH1A1 1254/4885 |
| US-20110112146-A1 | CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR3, CCR2 | KDM4E 4258/4885SMN1; SMN2 3745/4885ALDH1A1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.